Pulmonary Hypertension

My Hidden Struggles With Self-worth - Pulmonary Hypertension News My Hidden Struggles With Self-worth - Pulmonary Hypertension News Posted: 30 Oct 2020 07:00 AM PDT "You is kind. You is smart. You is important." These words are from Kathryn Stockett's book " The Help ." The maid, Aibileen, repeats this to the little girl, Mae Mobley, to remind her of her worth. As I read this part of the book, I couldn't help but long for someone to tell me the exact same thing. Although my exterior has always radiated confidence, happiness, and positivity, my hidden struggles lie beneath the surface. My struggles with self-worth run deep. I have struggled immensely with feelings of worthlessness and negative thinking for so many years of my life. I silenced emotional and physical trauma for decades and convinced myself I was somehow responsible for it. I filled my mind with self-blame and wrongfully shamed myself f...

Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection - - HIT Consultant Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection - - HIT Consultant Posted: 30 Oct 2020 04:39 PM PDT What You Should Know: – Mayo Clinic announced a collaboration with Vocalis Health to to research and develop new voice-based tools for screening, detecting and monitoring patient health, beginning with a study to identify vocal biomarkers to detect pulmonary hypertension (PH). – The clinical validation study will utilize Vocalis Health's proprietary software, which can operate on any connected voice platform (mobile, computer, tablet, etc.) to analyze patients' health based on voice recordings. – Following this initial phase, researchers will work to identify vocal biomarkers targeting additional diseases, symptoms and conditions. Mayo Clinic and Vocalis Health, Inc., a company pioneering AI-b...

Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma - DocWire News Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma - DocWire News Posted: 29 Oct 2020 11:00 PM PDT This article was originally published here Medicine (Baltimore). 2020 Oct 23;99(43):e22952. doi: 10.1097/MD.0000000000022952. ABSTRACT Pulmonary hypertension (PH) is a complication of multiple myeloma (MM); however, the clinical outcomes and prognosis are relatively not well known. We aimed to investigate the risk factors of transthoracic echocardiography-defined PH and its impact on the clinical outcome in patients with MM.A retrospective study was performed using data from the Chonnam National University Hwasun Hospital database for patients who underwent transthoracic echocardiography (TTE) within 1 month of the MM diagnosis ...

Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection - - HIT Consultant Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection - - HIT Consultant Posted: 30 Oct 2020 04:39 PM PDT What You Should Know: – Mayo Clinic announced a collaboration with Vocalis Health to to research and develop new voice-based tools for screening, detecting and monitoring patient health, beginning with a study to identify vocal biomarkers to detect pulmonary hypertension (PH). – The clinical validation study will utilize Vocalis Health's proprietary software, which can operate on any connected voice platform (mobile, computer, tablet, etc.) to analyze patients' health based on voice recordings. – Following this initial phase, researchers will work to identify vocal biomarkers targeting additional diseases, symptoms and conditions. Mayo Clinic and Vocalis Health, Inc., a company pioneering AI-b...

Dosing Begins in Phase 1b Trial of GMA301, Antibody Treatment for PAH - Pulmonary Hypertension News Dosing Begins in Phase 1b Trial of GMA301, Antibody Treatment for PAH - Pulmonary Hypertension News Posted: 30 Oct 2020 05:30 AM PDT A first patient has been dosed in a Phase 1b trial evaluating the safety and efficacy of GMA301 , an investigational antibody for the treatment of pulmonary arterial hypertension (PAH), Gmax Biopharm , the therapy's developer, announced in a press release . GMA301 is a humanized monoclonal antibody , meaning it is made by combining antibody fragments from rodents (mice or rats) and people. The rodent component binds to its target within the body, while the human component makes it less likely to trigger an immune reaction. Gmax reports that this is the first antibody treatment to be tested for PAH. GMA301 targets the endothelin receptor type A. Endothelin causes blood vessels to narrow, and is ...

Industry News: Mayo Clinic collaborates with Vocalis Health for clinical development of vocal biomarkers - SelectScience Industry News: Mayo Clinic collaborates with Vocalis Health for clinical development of vocal biomarkers - SelectScience Posted: 30 Oct 2020 09:22 AM PDT News Mayo Clinic collaborates with Vocalis Health for clinical development of vocal biomarkers Research study intends to develop vocal biomarker for pulmonary hypertension 30 Oct 2020 Mayo Clinic and Vocalis Health, Inc., a company pioneering AI-based vocal biomarkers for use in healthcare, have announced a collaboration to research and develop new voice-based tools for screening, detecting, and monitoring patient health. The collaboration will begin with a study to identify vocal biomarkers for pulmonary hypertension (PH) which could help physicians detect and treat PH in their patients. In a previous trial with Vocalis Health, the Mayo research tea...

Potential PAH Inhaled Therapy AV-101 to Advance With $72.6M in Funding - Pulmonary Hypertension News Potential PAH Inhaled Therapy AV-101 to Advance With $72.6M in Funding - Pulmonary Hypertension News Posted: 07 Aug 2020 12:00 AM PDT Aerovate Therapeutics received $72.6 million in Series A funding to advance trials testing AV-101 , an experimental inhaled version of imatinib for the treatment of  pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder that delivers imatinib directly to a patient's lungs. Benjamin Dake , PhD, Aerovate founding president, said this financing will allow the company to advance the clinical development of AV-101, with a registrational trial enrolling PAH patients scheduled to begin during the first half of 2021. "Sufferers of PAH desperately need a disease-modifying therapy," Dake said in a press release . According to Aerovate, an oral version of imatinib showed ...

Dosing Begins in Phase 1b Trial of GMA301, Antibody Treatment for PAH - Pulmonary Hypertension News Dosing Begins in Phase 1b Trial of GMA301, Antibody Treatment for PAH - Pulmonary Hypertension News Posted: 30 Oct 2020 05:30 AM PDT A first patient has been dosed in a Phase 1b trial evaluating the safety and efficacy of GMA301 , an investigational antibody for the treatment of pulmonary arterial hypertension (PAH), Gmax Biopharm , the therapy's developer, announced in a press release . GMA301 is a humanized monoclonal antibody , meaning it is made by combining antibody fragments from rodents (mice or rats) and people. The rodent component binds to its target within the body, while the human component makes it less likely to trigger an immune reaction. Gmax reports that this is the first antibody treatment to be tested for PAH. GMA301 targets the endothelin receptor type A. Endothelin causes blood vessels to narrow, and is ...